NVOS: Novo Integrated Sciences Price & Analysis

If you’ve searched for NVOS, you’ve probably landed on Novo Integrated Sciences, Inc., the small-cap healthcare company trading on the OTC Markets under that ticker. It’s a name that shows up a lot on penny stock forums and stock alert sites, usually attached to big percentage swings in either direction. Here’s what the company actually does, where the stock has been, and what to watch before you decide anything.

This article is for informational purposes only and isn’t financial advice. NVOS is a volatile, thinly traded stock, and you should do your own research or talk to a licensed financial advisor before making any investment decision.

What is NVOS stock?

NVOS is the ticker symbol for Novo Integrated Sciences, Inc., a U.S.-based holding company headquartered in Bellevue, Washington, with wholly owned subsidiaries operating in both the U.S. and Canada. The company was originally incorporated as Turbine Truck Engines, Inc. and changed its name in 2017 after pivoting into healthcare.

Novo operates in two main segments:

Healthcare Services: Through its Canadian subsidiary network, Novo provides multidisciplinary primary care and rehabilitation services, including physiotherapy, chiropractic care, occupational therapy, massage therapy, acupuncture, chiropody, concussion management, and stroke or brain injury rehabilitation. Much of this is delivered through community clinics, retirement homes, and long-term care facilities, plus eldercare and home-based physiotherapy programs.

Product Sales: This segment covers Novo’s medical technology and wellness products, including remote patient monitoring, telehealth platforms, and personalized health product lines sold through its subsidiaries.

For a deeper look at the company’s structure and history, our comprehensive overview of Novo Integrated Sciences (NVOS) breaks down each business line in more detail.

NVOS stock price and recent performance

NVOS has been a genuinely rough ride for shareholders. Over the past year the stock has traded in a wide range, from roughly $0.07 down to fractions of a cent, and multiple data providers now list it changing hands for well under a penny per share, with a market capitalization in the range of $1 million. That’s an extraordinary decline from its 52-week high and puts NVOS firmly in speculative penny-stock territory.

A few things stand out in the recent trading pattern:

• The stock has shown extremely high volatility, with daily swings of 20% or more not uncommon.
• Average daily trading volume has historically been in the tens of millions of shares, though volume has thinned out considerably during quiet stretches.
• Technical indicators have flipped between oversold readings and short-lived rallies, which is typical of low-priced stocks that attract momentum traders rather than long-term holders.

If you want a closer look at how the price has moved and what’s been driving the swings, we cover that in our piece on navigating the volatility in Novo Integrated Sciences’ stock price.

Financial performance

Novo’s most recently reported fiscal year showed revenue of about $13.3 million, a modest increase from the prior year’s $12.6 million. The company posted a net loss of roughly $16.2 million for the same period, up from the year before, with a deeply negative profit margin and negative operating cash flow.

In plain terms: revenue has grown slightly year over year, but the company continues to lose more money than it brings in. That combination- small revenue base, heavy losses, and a stock price that’s fallen sharply- is a pattern worth understanding before considering a position.

Novo has also relied on financing tools that are common among small-cap companies under financial pressure, including promissory notes and standby letter of credit monetization arrangements. These can raise cash in the short term but often come with terms that dilute existing shareholders or add repayment obligations.

Why NVOS attracts attention despite the losses

A few reasons keep NVOS on retail investors’ radar:

Low share price: A stock trading for fractions of a cent lets traders buy large numbers of shares with a small amount of capital, which appeals to people looking for a big percentage move rather than steady compounding.

Healthcare exposure: The underlying business- primary care, rehab services, and remote monitoring- sits in a sector that’s easy to understand and generally growing, even if this particular company hasn’t translated that into profits.

Periodic news catalysts: Announcements about financing arrangements, leadership changes, or partnership agreements have historically produced short-term price spikes, which keeps the stock on watchlists and stock-alert sites.

None of that changes the underlying financial picture. It just explains why the ticker keeps showing up in search results and on trading forums.

Risks to weigh before buying NVOS

• Dilution risk: Companies that repeatedly raise cash through notes or share issuances often increase the total share count over time, which can shrink the value of existing holdings even if the business itself doesn’t change.
• Liquidity risk: Thinly traded penny stocks can have wide bid-ask spreads, meaning the price you pay or receive may differ significantly from the last quoted price.
• Going-concern and cash flow pressure: Sustained net losses and negative operating cash flow mean the company depends on outside financing to keep operating, which isn’t guaranteed to continue on favorable terms.
• Volatility: Price swings of this size cut both ways. A stock that can double in a week can also lose most of its value just as fast.

Where to track NVOS stock and news

For real-time quotes, most investors check standard brokerage platforms or financial data sites rather than relying on social sentiment alone. That said, retail sentiment does move this stock, so it’s worth knowing where the conversation is happening. Our page on NVOS stock discussion on Stocktwits rounds up how traders are talking about recent moves, which can be a useful (if noisy) supplement to the actual financial filings.

NVOS stock FAQ

What does NVOS stand for? 

NVOS is the OTC Markets ticker for Novo Integrated Sciences, Inc., a healthcare services and wellness products holding company.

Is NVOS stock profitable? 

No. The company has reported net losses in recent fiscal years, with losses exceeding revenue by a wide margin.

Why has NVOS stock dropped so much? 

The decline reflects a mix of ongoing net losses, negative cash flow, reliance on dilutive financing, and the general risk profile of low-priced OTC stocks, which tend to see sharp drawdowns once early enthusiasm fades.

Is NVOS a good long-term investment? 

That depends entirely on your risk tolerance and research. The company has real revenue-generating operations in healthcare, but the financials show a business still working toward profitability, and the stock’s history shows extreme volatility. This isn’t a recommendation either way, just a summary of the public financial picture.

The bottom line

NVOS is a real operating business, not a shell company, with clinics, practitioners, and product lines generating actual revenue. But the stock price tells a different story from the balance sheet: heavy losses, dilution pressure, and volatility that’s scared off a lot of long-term holders. If you’re researching NVOS, read the actual SEC or OTC filings, not just the price charts, and size any position according to how much risk you’re genuinely comfortable taking on a speculative micro-cap.

For more coverage on NVOS and related healthcare and biotech tickers, browse our full analysis of Novo Integrated Sciences and Novosanis in the biotech sector, or check our About Us page to learn more about how we cover this stock.